When analyzing the genetic background of these tumor cell lines, it was surprising that the SNP (rs1042522) of p53 rather than the mutation of driver genes such as KRAS, MYC or BRAF, had a correlation with the distinct responses to serine supplementation in different tumor cells (Supplementary Fig. S1a). The gene discussed is KRAS; the disease is neoplasm.